GlassScriptPhysician profile
Abel Garduno
NPI 1336184787
$11,779.77
in general payments reported to CMS, 2019-2025
55 companies · $427 in 2025
The $427 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,254 · 2020: $1,181 · 2021: $1,858 · 2022: $3,936 · 2023: $1,619 · 2024: $505 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,451 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,451.33 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $2,025.90 | 2022 | |
| Novo Nordisk INC | $1,595.54 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,423.28 | 2019-2023 | Farxiga, Breztri |
| Abbvie INC. | $1,256.91 | 2019-2025 | |
| Lilly USA, LLC | $524.23 | 2019-2024 | Zepbound, Mounjaro |
| Amgen INC. | $429.18 | 2019-2025 | Tepezza |
| Glaxosmithkline, LLC. | $387.56 | 2019-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $309.43 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $277.59 | 2019-2023 | Verquvo |
| Dexcom, INC. | $226.87 | 2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $225.97 | 2019-2023 | Trintellix |
| Amarin Pharma, INC. | $194.31 | 2019-2020 | |
| Clarus Therapeutics INC. | $188.39 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $187.14 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $186.53 | 2020-2021 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abel Garduno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.